摘要
对比中国与全球情况可知,中国癌症发病率与世界平均水平接近,但死亡率与全球平均水平有差异.中国妇科恶性肿瘤负担日益加重,城乡差异较大,地区分布不均衡,癌症防控形势严峻.近年来,新技术、新药物[如免疫检查点抑制剂(immune checkpoint inhibitor,ICI)、抗体-药物偶联物(antibody-drug conjugate,ADC)等]陆续进入临床,为妇科恶性肿瘤的治疗带来新希望.本文对2023年度妇科恶性肿瘤的重大研究进展进行梳理,其中,在宫颈癌治疗方面,本文回顾了标准治疗模式革新、晚期复发转移性宫颈癌后线治疗的相关进展(ENGOT-cx11/GOG-3047/KEYNOTE-A18、KEYNOTE-826研究等);在卵巢癌治疗方面,本文总结了PARP抑制剂及免疫治疗、新诊断卵巢癌一线治疗、复发性卵巢癌治疗的最新进展(FLAMES、ANITA/ENGOT-Ov41/GEICO 69-O、NRG-GY004研究等);而在子宫内膜癌治疗方面,本文按照局部晚期子宫内膜癌治疗(GOG 258、Lunchbox研究等)、晚期/复发转移性子宫内膜癌治疗方面的进展(如ENGOT-EN6-NSGO/GOG-3031/RUBY研究等)进行综述,并对后线靶向治疗和免疫治疗探索进行总结(如KEYNOTE-775、ADAGIO等研究).本文从上述方面对妇科肿瘤2023年度的进展进行述评,旨在为临床实践及临床研究的开展提供参考.
Abstract
Compared with the global situation,it can be found that the cancer incidence in China is close to the world average level,but the mortality rate has difference compared with the global average level.The burden of gynecological cancers in China is increasing,with large differences between urban and rural areas and uneven regional distribution.Therefore,the situation of cancer prevention and control is still challenging.In recent years,new technologies and drugs,such as immune checkpoint inhibitors(ICIs)and antibody-drug conjugate(ADC),have been introduced into clinical practice,bringing new hope for the treatment of gynecological cancers.This article reviewed the major research progress of gynecological cancers in 2023.Among them,in terms of the progress of treatment for cervical cancer,we reviewed the innovation of standard treatment mode and the related progress of post-line treatment for advanced recurrent and metastatic cervical cancer(clinical research such as ENGOT-cx11/GOG-3047/KEYNOTE-A18,KEYNOTE-826).In terms of treatment for ovarian cancer,this review summarized the latest progress of PARP inhibitors,immunotherapy,first-line treatment of newly diagnosed ovarian cancer and treatment of recurrent ovarian cancer(FLAMES,ANITA/ENGOT-Ov41/GEICO 69-O,NRG-GY004,etc.).In terms of treatment for endometrial cancer,this study reviewed the progress in the treatment of locally advanced endometrial cancer(GOG 258,Lunchbox clinical research,etc.)and advanced/recurrent metastatic endometrial cancer(ENGOT-EN6-NSGO/GOG-3031/RUBY research,etc.),and summarized the exploration of back-line targeted immunotherapy(such as KEYNOTE-775,ADAGIO and other clinical studies).This study combed the progress of gynecological tumors in 2023 from the above aspects,aiming at providing reference for clinical practice and clinical research.
维普
万方数据